On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
Psoriatic Arthritis
ACR, American College of Rheumatology; DMARDs, disease-modifying antirheumatic drugs; HIV, human immunodeficiency virus; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; TB, tuberculosis; TNF, tumor necrosis factor.
DIP, distal interphalangeal joint; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs.
ACR, American College of Rheumatology; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DMARD, disease-modifying antirheumatic drug; HIV, human immunodeficiency virus; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; TB, tuberculosis.
Stable doses of oral corticosteroids (prednisone ≤10 mg/day or equivalent for ≥1 month) and NSAIDs (≥2 weeks) before study entry.
NSAIDs, nonsteroidal anti-inflammatory drugs.
ACR, American College of Rheumatology; ACTIVE, Assessing Apremilast Monotherapy in a Clinical Trial of Biologic-Naïve Patients With Psoriatic Arthritis; DMARD, disease-modifying antirheumatic drug; HIV, human immunodeficiency virus; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Wells AF, Edwards CJ, Kivitz AJ, et al. Rheumatology (Oxford). 2018;57(7):1253-1263. 4. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. J Rheumatol. 2015;42(3):479-488. 5. Cutolo M, Myerson GE, Fleischmann RM, et al. J Rheumatol. 2016;43(9):1724-1734. 6. Edwards CJ, Blanco JC, Crowley J, et al. Ann Rheum Dis. 2016;75(6):1065-1073. 7. Nash P, Ohson K, Walsh J, et al. Ann Rheum Dis. 2018;77(5):690-698.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.